Testing effectiveness (Phase 2)Looking for participantsNCT05281406
What this trial is testing
Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)
Who this might be right for
NSCLC Stage IIIBNSCLC Stage IV
Goethe University 50